WO2003032913A3 - Methods and compositions for targeting proteins across the blood brain barrier - Google Patents
Methods and compositions for targeting proteins across the blood brain barrier Download PDFInfo
- Publication number
- WO2003032913A3 WO2003032913A3 PCT/US2002/032996 US0232996W WO03032913A3 WO 2003032913 A3 WO2003032913 A3 WO 2003032913A3 US 0232996 W US0232996 W US 0232996W WO 03032913 A3 WO03032913 A3 WO 03032913A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compositions
- methods
- brain
- igf
- brain barrier
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000008685 targeting Effects 0.000 title abstract 3
- 230000008499 blood brain barrier function Effects 0.000 title 1
- 210000001218 blood-brain barrier Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002347910A AU2002347910A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting proteins across the blood brain barrier |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32965001P | 2001-10-16 | 2001-10-16 | |
US60/329,650 | 2001-10-16 | ||
US10/136,639 | 2002-04-30 | ||
US10/136,639 US20030072761A1 (en) | 2001-10-16 | 2002-04-30 | Methods and compositions for targeting proteins across the blood brain barrier |
US10/136,841 US7396811B2 (en) | 2001-04-30 | 2002-04-30 | Subcellular targeting of therapeutic proteins |
US10/136,841 | 2002-04-30 | ||
US38445202P | 2002-05-29 | 2002-05-29 | |
US60/384,452 | 2002-05-29 | ||
US38601902P | 2002-06-05 | 2002-06-05 | |
US60/386,019 | 2002-06-05 | ||
US40881602P | 2002-09-06 | 2002-09-06 | |
US60/408,816 | 2002-09-06 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003032913A2 WO2003032913A2 (en) | 2003-04-24 |
WO2003032913A9 WO2003032913A9 (en) | 2004-04-29 |
WO2003032913A3 true WO2003032913A3 (en) | 2004-08-12 |
Family
ID=27558195
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/032996 WO2003032913A2 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting proteins across the blood brain barrier |
PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/032968 WO2003032727A1 (en) | 2001-10-16 | 2002-10-16 | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1446007A4 (en) |
JP (2) | JP2005506340A (en) |
AU (3) | AU2002347910A1 (en) |
CA (1) | CA2463473A1 (en) |
IL (1) | IL161352A0 (en) |
WO (2) | WO2003032913A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7396811B2 (en) | 2001-04-30 | 2008-07-08 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
CA2463473A1 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Targeted therapeutic proteins |
AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
AU2005212435B2 (en) * | 2004-02-10 | 2010-09-09 | Biomarin Pharmaceutical Inc. | Acid alpha-glucosidase and fragments thereof |
CA3184105A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
SI2234600T1 (en) * | 2007-12-21 | 2014-12-31 | F. Hoffmann-La Roche Ag | Antibody formulation |
AU2009244148B2 (en) | 2008-05-07 | 2014-10-09 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
WO2010148253A2 (en) | 2009-06-17 | 2010-12-23 | Zystor Therapeutics, Inc. | Formulations for lysosomal enzymes |
RU2012154576A (en) | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | METHODS AND COMPOSITIONS FOR DELIVERY TO CNS HEPARAN-N-SULFATASE |
RU2660348C2 (en) | 2010-06-25 | 2018-07-05 | Шир Хьюман Дженетик Терапис, Инк. | Methods and compositions for cns delivery of iduronate-2-sulfatase |
EP3103469B1 (en) | 2010-06-25 | 2020-12-09 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
KR20130043166A (en) * | 2010-06-25 | 2013-04-29 | 샤이어 휴먼 지네틱 테라피즈 인크. | Treatment of sanfilippo syndrome type b |
PL2585104T3 (en) | 2010-06-25 | 2020-01-31 | Shire Human Genetic Therapies, Inc. | Methods and compositions for cns delivery of arylsulfatase a |
PT2588130T (en) * | 2010-06-25 | 2016-11-25 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
CA2857567A1 (en) * | 2011-12-01 | 2013-06-06 | Angiochem Inc. | Targeted lysosomal enzyme compounds |
US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
EP2885318A4 (en) | 2012-08-14 | 2016-03-30 | Angiochem Inc | Peptide-dendrimer conjugates and uses thereof |
DK2925776T3 (en) | 2012-11-27 | 2018-09-03 | Biomarin Pharm Inc | TARGETED THERAPEUTIC LYSOSOMAL ENZYMUS FUSION PROTEINS AND APPLICATIONS THEREOF |
CA2902289A1 (en) * | 2013-03-15 | 2014-09-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Low concentration antibody formulations |
SG11201608025QA (en) | 2014-04-01 | 2016-10-28 | Swedish Orphan Biovitrum Ab Publ | Modified sulfamidase and production thereof |
JP6823055B2 (en) | 2015-06-15 | 2021-01-27 | アンジオケム インコーポレーテッド | How to treat soft meningeal carcinomatosis |
RU2751235C2 (en) | 2016-02-24 | 2021-07-12 | Байомарин Фармасьютикал Инк. | Therapeutic targeted fusion proteins based on lysosomal enzymes, relevant compositions and their applications |
EP3788064A1 (en) * | 2018-04-30 | 2021-03-10 | Amicus Therapeutics, Inc. | Gene therapy constructs and methods of use |
MX2021004188A (en) | 2018-10-10 | 2021-09-08 | Amicus Therapeutics Inc | Disulfide bond stabilized polypeptide compositions and methods of use. |
JP7458404B2 (en) | 2018-12-20 | 2024-03-29 | アーマジェン・インコーポレイテッド | Purification of iduronic acid-2-sulfatase immunoglobulin fusion protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
WO1991004014A1 (en) * | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
US6472140B1 (en) * | 1997-09-05 | 2002-10-29 | The General Hospital Corporation | α-2- macroglobulin therapies and drug screening methods for Alzheimer's disease. |
US7396811B2 (en) * | 2001-04-30 | 2008-07-08 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
CA2463473A1 (en) * | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Targeted therapeutic proteins |
AU2003237314B2 (en) * | 2002-05-29 | 2010-03-04 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
-
2002
- 2002-10-16 CA CA002463473A patent/CA2463473A1/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032996 patent/WO2003032913A2/en not_active Application Discontinuation
- 2002-10-16 EP EP02801739A patent/EP1446007A4/en not_active Withdrawn
- 2002-10-16 AU AU2002347910A patent/AU2002347910A1/en not_active Abandoned
- 2002-10-16 AU AU2002362930A patent/AU2002362930A2/en not_active Abandoned
- 2002-10-16 WO PCT/US2002/032968 patent/WO2003032727A1/en active Application Filing
- 2002-10-16 IL IL16135202A patent/IL161352A0/en unknown
- 2002-10-16 JP JP2003535542A patent/JP2005506340A/en active Pending
-
2009
- 2009-06-16 JP JP2009143436A patent/JP2009203241A/en active Pending
-
2010
- 2010-08-25 AU AU2010214643A patent/AU2010214643A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
Also Published As
Publication number | Publication date |
---|---|
JP2005506340A (en) | 2005-03-03 |
WO2003032913A2 (en) | 2003-04-24 |
AU2010214643A1 (en) | 2010-09-16 |
AU2002362930A2 (en) | 2003-04-28 |
WO2003032727A1 (en) | 2003-04-24 |
EP1446007A4 (en) | 2005-12-07 |
WO2003032913A9 (en) | 2004-04-29 |
AU2002347910A1 (en) | 2003-04-28 |
EP1446007A1 (en) | 2004-08-18 |
CA2463473A1 (en) | 2003-04-24 |
IL161352A0 (en) | 2004-09-27 |
JP2009203241A (en) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003032913A3 (en) | Methods and compositions for targeting proteins across the blood brain barrier | |
WO2004047863A3 (en) | Genetic products differentially expressed in tumors and the use thereof | |
MY154826A (en) | Fusion protein capable of binding vegf | |
WO2006007560A3 (en) | Targeted protein replacement for the treatment of lysosomal storage disorders | |
WO2007091250A8 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
WO2007035474A3 (en) | Transdermal delivery peptides and method of use thereof | |
EP0744408A3 (en) | Rhesus ob protein and DNA | |
WO2004087766A3 (en) | Peptabody for cancer treatment | |
WO2002092013A3 (en) | Methods for treating liver disease and liver damage with growth hormone and foxm1b | |
WO2005026205A3 (en) | Genetic products which are differentially expressed in tumours and use thereof | |
WO2000078327A3 (en) | Agents for treating malignant diseases using e1a-deficient adenoviruses with yb-1 protein-dependent replication | |
DK1144600T3 (en) | Act-3 nucleic acid, polypeptides and uses thereof | |
WO2003098223A3 (en) | A method for killing cells by inhibiting histone activity in the cell | |
WO2000067697A3 (en) | Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells | |
WO2003003977A3 (en) | Compositions and methods for the treatment of body weight disorders, including obesity | |
WO2002014369A3 (en) | Human kininogen d5 domain polypeptides and their use | |
WO2001002550A3 (en) | Cell death related drug targets in yeast and fungi | |
WO2004047758A3 (en) | Methods of therapy and diagnosis using targeting of cells that express p2y10 | |
WO2003012121A3 (en) | Collagen xxii, a novel human collagen and uses thereof | |
WO2003083037A3 (en) | Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides | |
WO2003018829A3 (en) | 6299, a human zinc carboxypeptidase family member and uses therefor | |
WO2001070948A3 (en) | Methods and compositions for elucidating protein expression profiles in cells | |
WO2004049917A3 (en) | Methods of therapy and diagnosis using targeting of cells that express ly-9 | |
WO2002079222A3 (en) | Fusion proteins for specific treatment of cancer and auto-immune diseases | |
WO2004053061A3 (en) | Methods of therapy and diagnosis using targeting of cells that express lax |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |